Tianda Pharmaceuticals（00455）“Anti-Epidemic Formula 1” granules approved for entry into the Australian Register of Therapeutic Goods as a listed medicine (Sina Finance)
07.05.2020
Tianda Pharmaceuticals published its announcement. The Anti-Epidemic Formula 1 granules, a Traditional Chinese Medicine (“TCM”) product of the Group, manufactured by Tianda Pharmaceuticals (Zhuhai) Limited, a wholly-owned and Australian GMP-accredited subsidiary of the Company, has been approved for entry into the Australian Register of Therapeutic Goods as a listed medicine. This will allow the Group to supply and sell Anti-Epidemic Formula 1 in Australia, which will be managed by Tianda Pharmaceuticals (Australia) Pty Ltd., a wholly-owned subsidiary of the Company based in Australia. This marks the expansion of the Group’s TCM business to Australia from the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA”), and an important first step to the global roll-out.
The announcement indicated that the TCM Anti-Epidemic Formulae series comprises Anti-Epidemic Formula 1 (for prevention), Anti-Epidemic Formula 2 (for remedy) and Anti-Epidemic Formula 3 (for rehabilitation), which have been specially developed by the Group and a team of authoritative TCM experts at the outset of the COVID-19 outbreak, consisting of Professor Zhou Chaofan, the former leader of the TCM section of Chinese Pharmacopoeia Commission, Professor Lu Xiangzhi, Senior Adviser of World Federation of Chinese Medicine Societies, renowned TCM Masters such as Dr. Wang Shimin, Dr. Shen Baofan and Dr. Lei Zhongyi, and the well-known TCM clinician Dr. Du Huifang as well. The joint team carried out in-depth investigation of the cause and pathogenesis of the COVID-19 outbreak, integrating the theory and practice of TCM with modern pharmacological research, prescribing medicinal substances and combining classical formulae in a scientific and balanced manner.
Anti-Epidemic Formula 1 is a preventive prescription mainly for improving people’s immune system, helping them to prevent influenza or COVID-19. Anti-Epidemic Formula 2 is a remedial prescription for relieving the symptoms of influenza or COVID-19. Anti-Epidemic Formula 3 is a rehabilitative prescription for recovered influenza or COVID-19 patients’ rehabilitation, helping them to boost their physical strength and immunity.
From late February to early April this year, the Group launched anti-epidemic campaigns in Guangdong, Hong Kong and Macau, among other areas, to provide complimentary TCM consultation and Anti-Epidemic Formula 1 to more than 1,000 individuals. Additionally, over 1,500 doses of Anti-Epidemic Formula 1 have been sold in the Zhuhai TDMall, the Group’s flagship Chinese medicine clinic in Zhuhai. As shown in the follow-up interview with the recipients of the medicine, there was no COVID-19 infection and more than 98.35% of them did not get a cold during the relevant observation period, with the respondents saying that their body condition had improved. Anti-Epidemic Formula 1, which has been developed by the TCM experts by combining their clinical experience and classical formulae, and prepared by using scientific extraction methods, has been shown to be effective and safe for use over the past few months. In that connection, the Group has made further plans for the product development of Anti-Epidemic Formula 1, Anti-Epidemic Formula 2 and Anti-Epidemic Formula 3 altogether to better serve the general public.
The other major development in the Group’s TCM business segment is the investment in the establishment of TDMall, a new style Chinese medicine clinic chain. The Group has opened one flagship TDMall in each of Zhuhai, Guangdong province and Causeway Bay, Hong Kong in May last year and February this year respectively. While focusing on the GBA, TDMall seeks development opportunities in all parts of China and the world. At the same time, the Group is making enhancements to its “Cloud TDMall” which offers online AI-enabled remote medical consultation, with the ultimate goal of building a Cloud-based TCM anti-epidemic platform. This is aimed at supporting the global fight against the pandemic, representing the Group’s continuing efforts to bring benefits to human health and wellbeing.
Source: Sina Finance
This is an English translation of the original Chinese text. If there is any inconsistency or ambiguity between the English version and the Chinese version, the Chinese version shall prevail.